---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011618"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:52:22.262597+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus Q2 net loss narrows to $12.9M; UDENYCA sales up 60% YoY; appoints new CFO

## Summary
- Q2 2024 net revenue $65.0M (+11% YoY); net loss $12.9M ($0.11 loss per share) vs $42.9M loss in Q2 2023.
- UDENYCA net sales $50.9M (+60% YoY); market share 29% (+4 pts QoQ). LOQTORZI net sales $3.8M in first launch quarter.
- Divestitures of CIMERLI and YUSIMRY generated $177.7M gain in H1 2024; repaid $250M term loan, replaced with $38.7M facility.
- Pipeline: CHS-114 expansion cohorts enrolling; CHS-1000 IND cleared; casdozokitug Phase 2 planned Q4 2024.
- Bryan McMichael appointed CFO, effective Aug 1, 2024; base salary $476K, 50% target bonus, 75,000 stock option grant.

## SEC filing metadata
- accession: 0001558370-24-011618
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024011618/0001558370-24-011618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024011618/chrs-20240807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011618
- JSON: https://secwatch.observer/filing/0001558370-24-011618.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011618.txt

## Key facts
- Executive change
  Bryan McMichael was appointed as Chief Financial Officer at Coherus Oncology, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On August 7, 2024, the Company’s board of directors appointed Bryan McMichael, age 46, the Company’s current Interim Chief Financial Officer, Executive Vice President, Accounting, Corporate Controller, to serve as the Company’s Chief Financial Officer effective August 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837024011618/0001558370-24-011618-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.